Metabolics
Objectives
The Bristol-Myers Squibb ISR application process provides a framework and allows investigators to work from a common set of criteria, requirements and schedule of events. The process is designed to ensure scientific rigor and patient safety while supporting unique research ideas and providing insights into areas of unmet medical need.
Saxagliptin
RFP-US-12-CV181-016
Characterization of the mechanisms through which saxagliptin may potentially provide cardiovascular benefit via GLP-1 and (with an emphasis on) non-GLP-1 pathways through effects on:
- Vascular inflammation and endothelial cell function
- Cardiomyopathy
- Cardiac steathosis
- Tissue repair post acute cardiac damage
- SDF-1 expression and modulation of progenitor cell traffic
RFP-US-12-CV181-020
Characterization of the mechanisms through which saxagliptin may potentially provide benefit via incretin and non-incretin pathways through effects on:
- Inflammation in adipose tissue and muscle
- Lipogenesis, adipocyte differentiation, and fat redistribution
- Peripheral and renal vascular inflammation
- Gut barrier function and integrity
RFP-US-12-CV181-019
Explore the effects of saxagliptin on:
- Alpha cell function
- Glucagon secretion
RFP-US-12-CV181-018
Explore the safety and efficacy of saxagliptin in patients with HbA1C closer to glycemic goals, with special consideration of hypoglycemia: e.g., investigate the relationship between glucose excursions and hypoglycemia.
RFP-US-12-CV181-017
Explore the effects of saxagliptin on renal function as they relate to diabetic nephropathy and hypertension; e.g., investigate the role of DPP4 interaction with NHE3 in the renal tubules.